Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

In a single inpatient case study, a schizophrenic patient with tardive dysk inesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Wi thin 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia i mproved; 10 weeks after starting treatment tardive dyskinesia stopped compl etely. Over the same period, dopamine D-2 receptor occupancy decreased subs tantially, as measured by IBZM-SPECT after 14 and 77 days of treatment. (C) 2000 Lippincott Williams & Wilkins.